JP Morgan
At JP Morgan, Myriad Genetics Says Q4 Test Volumes Disappointing, Firm Preps New Launches in 2025
Premium
The firm announced preliminary full-year 2024 revenue estimates that were slightly below expectations.
Executives also provided additional information on the firm's Q4 2024 financial performance.
The firm said preliminary core Q4 2024 revenues are expected to be flat, exceeding prior expectations, while its China business has stabilized and will recover.
Brian Blaser said the firm has eliminated certain C-suite positions and implemented strategies to improve the firms profitability.
Revvity Enters Into $1.5B Credit Facility
The firm said that the unsecured $1.5 billion revolving credit facility through 2030 replaces another $1.5 billion credit facility through 2026.
Apr 22, 2024
JP Morgan Downgrades Pacific Biosciences to Neutral
Sep 8, 2022
Morgan Health Invests $20M in LetsGetChecked
Aug 11, 2022
JP Morgan Downgrades Seer to Neutral
Aug 25, 2021
PerkinElmer Reaches Deal for $1.5B Credit Facility
Aug 12, 2021